Business Context and Reporting Period
Company: CME Group Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2008
Event: Entry into a definitive Agreement and Plan of Merger to acquire NYMEX Holdings, Inc. and its subsidiary, New York Mercantile Exchange, Inc. (NYMEX).
Key Financial Metrics and Transaction Terms
This filing details a merger agreement rather than periodic financial results. Key transaction metrics include:
- Consideration Structure: NYMEX Holdings stockholders may elect cash or CME Group Class A common stock.
- Cash Component: Mandatory minimum aggregate cash consideration of $3.4 billion.
- Stock Component: Estimated issuance of 12.5 million shares of CME Group Class A common stock.
- Per-Share Cash Formula: $36.00 plus 0.1323 times the average closing sale price of CME Group Class A stock over a specific 10-day period prior to closing.
- Membership Buyout: NYMEX will offer to purchase 100% of outstanding Class A membership interests for up to $500 million in aggregate (approx. $612,000 per membership).
- Termination Fee: $308 million payable by either party under specific termination circumstances.
Note: The filing does not provide CME Group's current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Conditions
The filing announces a material definitive agreement that will significantly alter CME Group's corporate structure and market position upon closing. The transaction is subject to several closing conditions, including:
- Approval by NYMEX Holdings stockholders.
- Approval by CME Group stockholders for the amendment of its certificate of incorporation and issuance of new shares.
- Approval by NYMEX Class A members for amendments to its charter and bylaws.
- Purchase of at least 75% of NYMEX Class A memberships.
- Effectiveness of a Form S-4 registration statement.
- Receipt of required regulatory approvals.
Outlook, Risks, and Management Commentary
Management Action: The Boards of Directors for CME Group, Merger Sub, NYMEX Holdings, and NYMEX have approved the Merger Agreement. Voting and Support Agreements have been signed with major stakeholders, including General Atlantic Partners (approx. 6.2 million shares) and NYMEX leadership.
Tax Status: The Merger is intended to qualify as a tax-free reorganization for federal income tax purposes.
Risks and Contingencies:
- Proration Risk: If the total elected cash consideration deviates from the $3.4 billion mandatory component, the mix of cash and stock may be adjusted (prorated) to meet the requirement.
- Regulatory Risk: Closing is contingent on regulatory approvals.
- Termination Risk: The deal may be terminated under certain conditions, triggering a $308 million fee.
Investor Guidance: Investors are urged to read the joint proxy statement/prospectus when filed, as it will contain important information not available in this 8-K.
Key Facts for Investor Verification
- Verify the final exchange ratio and cash/stock split once the "Average CME Price" is calculated near the closing date.
- Confirm the status of the 75% NYMEX Class A membership purchase requirement.
- Monitor the filing and approval of the Form S-4 registration statement.
- Review the upcoming joint proxy statement/prospectus for detailed financial data and risk factors.
- Assess the impact of the $308 million termination fee on potential deal failure scenarios.